The US market for PV devices is an evolving market, where a large undiagnosed patient population and innovative product launches will allow for moderate expansion through 2029, despite the negative impact of the COVID-19 pandemic on procedures, unit sales, and revenues in the short term.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for PV devices in the US across a 10-year period.

The COVID-19 pandemic will negatively impact the overall PV procedures and revenues in the short term.

What factors contribute to the market decline?

To what degree will the pandemic affect different PV device segments?

How soon will procedure volumes, sales, and revenues recover over the forecast period?

The publication of the Katsanos study in late 2018 and its fallout had a significant impact on the DCB market in 2019

What effect did data highlighting safety concerns with paclitaxel-coated devices have on the DCB market?

To what degree was DCBs  adoption in the US curtailed over the forecast period?

How many competitors will enter the DCB market, and who will gain the most market share?

How were other PTA balloon catheter markets effected by turmoil in the DCB market?

How will DCB uptake affect other PV devices such as stents, and atherectomy devices?

Which new indications will drive growth in the DCB market?

A focus on noninvasive lower-extremity revascularization will contribute to increasing endovascular procedure volumes.

How will the adoption of and familiarity with CTO crossing devices affect the fem-pop and infrapop device markets?

How has CMS reimbursement affected the use of atherectomy by site of service?

What impact will the rising role of office-based procedures have on the lower-extremity market?

Table of contents

  • Peripheral Vascular Devices - Market Insights - United States

Author(s): Jackie Liu

Jackie Liu is an analyst within the Cardiovascular Medtech Insights team at DRG (Part of Clarivate), specializing in peripheral vascular device markets. Jackie holds a PhD in Molecular Genetics and a MPH in Epidemiology from the University of Toronto. Prior to her current position, Jackie worked at multiple public health organizations in Ontario, gaining extensive experience with reporting and analyzing large-scale health data.